Please login to the form below

Not currently logged in
Email:
Password:

Lucid strikes £11m investment deal with equity firm LDC

Will use the new funds to underpin its infrastructure as it grows

Lucid Group Lucid has agreed an £11m investment deal with private equity company LDC to support its US expansion and increase its infrastructure.

The medical communications group has been growing rapidly, most recently launching a new strategic consultancy and winning a Queen’s Award for international trade earlier this year.

Its agreement with LDC will see the firm, which is the private equity arm of the UK’s Lloyds Banking Group, take a minority investment in Lucid.

LDC investment directors Christian Bruning and Rob Apollo will join the group’s board, with Tim Trotter - current chairman of PEI Media and chief executive chairman of Ludgate Group - appointed as non-executive chairman as a part of the deal.

Lucid’s founders Dennis O’Brien and Jan Steele will continue to lead the business.

O’Brien said: “We felt the time was right to bring on board a strategic partner, and in LDC we have an experienced investor with a strong track record in the healthcare sector.

“From the outset, they have had a flexible approach to the investment, structuring the deal on terms that worked for us.

“We’re now best placed to maximise the growth potential of Lucid and solidify our position as thought leaders and innovators in the medical education market.”

Lucid, which employs over 100 people, has offices in London, Beaconsfield and New York, and has seen a 30% growth in the past two years.

Christian Bruning, investment director at LDC London, said: “In Dennis, Jan and their management we have an experienced team at the helm of the business and we look forward to working alongside them to support the next phase of growth and expansion to build further on the Lucid brand.

Article by
Gemma Jones

12th June 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics